This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
DUBLIN, Ireland, June 18, 2013 (GLOBE NEWSWIRE) -- In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc (Nasdaq:WCRX) (the "
Company") confirms that, as of the close of business on June 12, 2013, the Company's issued share capital consisted of 251,123,743 ordinary shares, par value US$0.01 per share (the "
Ordinary Shares"). The CUSIP number for the Ordinary Shares is G94368100.
The Company also confirms that, as of the close of business on June 12, 2013, there were outstanding 2,265,383 restricted share units (the "
Restricted Share Units") and 6,205,434 options to purchase Ordinary Shares (the "
Share Options") granted by the Company. Upon vesting, each Restricted Share Unit entitles the holder to receive one Ordinary Share, and each Share Option entitles the holder to purchase one Ordinary Share at the applicable exercise price.
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, primarily in North America. We are a fully integrated Company with internal resources dedicated to the development, manufacture and promotion of our products. WCRX-G.
The holder of 1% or more of any relevant securities in the Company may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules.
The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.